Persons Reported to be living with HIV infection and with AIDS reported
Year Adults/Adolescents Children Under 13 Years old Total Cumulative Totals
  HIV AIDS HIV AIDS HIV AIDS Adults / Adolescents Children Under 13 Years old Total
2000 6,975 5,448 88 49 5,448 5,497 12,423 137 12,560
2001

7,269

5,805

 95 46 7,364 5,851 13,074 141 13,215
2002 7,932 6,856 131 46 8,063 6,902 14,788 177 14,965
                   

 

 

HIV Infection Cases  from areas with confidential HIV infection reporting
Year   Cumulative Totals
    Adults / Adolescents Children Under 13 Years old Total
2000 841 7,335 116 7,451
2001 830 7,692 125 7,817
2002 901 7,932 131 8,063
         

 

Adult/Adolescent HIV infection and AIDS cases reported in the United States
Year Males Females
  HIV AIDS HIV AIDS
2000 540 482 293 191
2001 523 613 296 248
         

 

New Pediatric AIDS cases reported

Year
2000 6
2001 0

 

AIDS cases and annual rates per 100,000 population by Metropolitan area reported through 2001

 

 1999

2000

2001

Cumulative Totals
City No No. No. Adults / Adolescents Children under 13 Years old Total

Baton Rouge

 189 143 221 2,110 19 2,129
New Orleans 415 332 312 7,185 67 7,252

 

Cumulative AIDS Cases

Cumulative Number of AIDS Cases, Reported through 2002 14,624
Cumulative Number of Adult/Adolescent AIDS Cases, Reported through 2002 14,494
Cumulative Number of AIDS Cases in Children <13, Reported through 2002 130

Distribution of Cumulative Adult/Adolescent AIDS Cases by Gender, Reported through June 2002
  LA USA
Men 11,501 680,909
Women 2,340 146,298
Total 13,841 827,208

 

New AIDS Cases

New AIDS Cases, Reported through 2002 1,167
New Adult/Adolescent AIDS Cases, Reported in 2001 861
New AIDS Cases in Children <13, Reported through December 2001 0

Distribution of New Adult/Adolescent AIDS Cases by Gender, Reported in 2001
  LA USA
Men 613 31,901
Women 248 11,082
Total 861 42,983

 

Persons Living with AIDS

Estimated Number of Persons Living with AIDS at the End of 2002 6,902
Estimated Number of Adults/Adolescents Living with AIDS at the End of 2002 6,856
Estimated Number of Children Living with AIDS at the End of 2002 46
HIV Infection Cases Reported in 2002 901

 

 
Total Deaths Reported through 2000, due to AIDS = 7,706
HIV Reporting Requirements ?   Yes, Name Based.
 
HIV Testing Options?  Anonymous and Confidential testing
Definitions: Anonymous test: Individual does NOT use their name, and a name is not associated with test result. Anonymous tests are offered at anonymous testing centers, available in many, but not all, states.
Confidential test: Individual DOES use their name. If test is positive, individual's name will be known to their health care provider and, potentially, to other health care professionals and, in some cases, your state's Department of Health.
 
HIV Testing for Mothers and Newborns
Voluntary or Mandatory Testing?  Providers required to offer HIV test. Providers are required by law to offer HIV testing to pregnant women.
Voluntary HIV Testing: All states and the District of Columbia have certified to the CDC that they have measures in place to implement the CDC's 1995 recommendations on HIV counseling and testing of pregnant women.  The CDC's 1995 recommendations state that HIV testing of pregnant women and infants should be voluntary and providers must obtain informed consent for testing as required by their state laws.  Voluntary testing is noted if the state follows the CDC guidelines but does not have specific guidelines for testing of mothers and newborns.
 
Status of State Medicaid Expansion Efforts for People with HIV
Approved 1115 Waiver, TWWIIA demonstration? NO
Definitions: 1115 Waivers: Section 1115 of the Social Security Act authorizes the executive branch of the Federal government to waive the statutory and regulatory provisions of the Medicaid program. States have used "1115 waivers" to make changes in eligibility, benefits, and other areas of their Medicaid programs. The Centers for Medicare and Medicaid Services (CMS--formerly known as the Health Care Financing Administration) and several states have been analyzing the implications of expanding Medicaid eligibility to people with HIV prior to disability through the use of Section 1115 waivers of the Social Security Act. To use 1115 waivers, states face several challenges, particularly the need to demonstrate "budget neutrality" to the Medicaid program - that the costs of an expansion over a designated period of time (usually 5 years) would not exceed the costs to Medicaid in the absence of the expansion.
Ticket to Work/Work Incentives Improvement Act of 1999: TWWIIA expanded State options under Medicaid by creating new Medicaid buy-in options for working individuals with disabilities and extended Medicare cover-age for working individuals with disabilities. The Act also authorized state demonstration programs to provide Medicaid to workers with potentially severe disabilities, including HIV/AIDS, who are not yet disabled but whose health conditions could be expected to cause disability.
Notes: Most people with HIV who qualify for Medicaid do so by meeting the program’s income and disability standards once their illness has already progressed. Many low income people with HIV may be faced with of having their eligibility postponed until they become disabled, even though there are therapies available that may prevent disability and national treatment guidelines recommend access to early treatment. 1115 Waivers and TWWIIA demonstrations are two ways in which states have sought to address this limitation.

 
Sterile Syringe Exchange Programs?  Yes
Notes: U.S. totals include data from the United States (50 states and the District of Columbia), and from U.S. dependencies, possessions, and independent nations in free association with the United States.
Definitions: Programs in operation: includes both state-sanctioned syringe exchange programs and non-sanctioned programs. Because their operation may not necessarily be authorized, it is difficult to account for an exact number of syringe exchange programs operation across the country; therefore, the list may not be comprehensive.
 
STD/HIV/AIDS Education Requirement?  No, If taught voluntarily, must stress abstinence.
 
Minors' Right to Consent to HIV/STD Services?  Yes. Physician may notify parents.
 

 

Total Ryan White Funding, FY2000   $25,638,617 FY2002  $34,763,202

 

CDC HIV Prevention Funding for States
 FY2001  $5,285,213

 FY2003   $5,046,302

 

Total Federal and State Funding for ADAP, FY2001  $10,122,466

Definitions: ADAPs: AIDS Drug Assistance Programs (ADAPs), authorized under Title II of the Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, provide HIV-related prescription drugs to underinsured and uninsured individuals living with HIV/AIDS. Each state or territory administers its own ADAP.

 

AIDS Drug Assistance Programs (ADAPs)
Source Kaiser Family Foundation

Total ADAP Clients Served, June 2002  
  LA
#		 US
#
   1,536 80,035

 
ADAP Clients Served by Sex, June 2002  
  LA
#		 LA
%		 US
#		 US
%
  Male 1,198 78 62,034 78
  Female 338 22 16,702 21
  Total 1,536 100 79,531 100

 
ADAP Clients Served by Race/Ethnicity, June 2002  
  LA
#		 LA
%		 US
#		 US
%
  White 645 42 29,426 37
  Black 829 54 26,245 33
  Hispanic 46 3 19,883 25
  Asian/Pacific Islander 0 0 795 1
  American Indian/Alaskan Native 0 0 795 1
  Other 15 1 795 1
  Total 1,536 100 79,531 100

 
ADAP Clients Served by Age, June 2002  
  LA
#		 LA
%		 US
#		 US
%
  <13 years old 15 1 795 1
  13-19 years old 0 0 0 1 0 1
  20-44 years old 968 63 50,105 63
  >44 years old 522 34 27,836 35
  Total 1,536 98 79,531 100

 
ADAP Clients Served by Income, June 2002  
  LA
#		 LA
%		 US
#		 US
%
  <100% FPL 691 45 38,175 48
  101-200% FPL 845 55 26,245 33
  201-300% FPL 0 0 8,748 11
  301-400% FPL 0 0 3,181 4
  >400% FPL 0 0 1,591 2
  Total 1,536 100 79,531 100

 
Insurance Coverage of ADAP Clients, June 2002  
  LA
#		 LA
%		 US
#		 US
%
  Medicaid 0 0 0 10
  Medicare 92 6 0 6
  Private 0 0 0 13

 
National ADAP Budget, Total Federal and State Sources, FY 2002  
  LA
$		 US
$
   12,720,074 878,610,754

 
National ADAP Budget by Source, FY 2002  
  LA
$		 LA
%		 US
$		 US
%
  ADAP Earmark 11,060,885 87 619,830,000 71
  Title II Base 0 0 28,886,192 3
  State 0 0 160,385,979 18
  Title I 0 0 19,736,619 2
  Other Federal 0 0 30,941,439 4
  ADAP Supplemental Grants 1,659,189 13 19,170,000 2
  Total 12,720,074 100 878,610,754 100

 
Total ADAP Drug Expenditures, June 2002  
  LA
$		 US
$
   1,103,046 70,705,142

 
ADAP Drug Expenditures by Drug Class, June 2002  
  LA
$		 LA
%		 US
$		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 603,603 55 31,486,146 49
  non-Nucleoside Reverse Transcriptase Inhibitors 134,757 12 7,940,575 12
  Protease Inhibitors 357,764 32 16,433,502 25
  Opportunistic Infections/Other 6,921 1 9,015,329 14
  Total 1,103,046 100 64,875,793 100

 
Total ADAP Prescriptions Filled, June 2002  
  LA
#		 US
#
   3,624 257,279

 
ADAP Prescriptions Filled by Drug Class, June 2002  
  LA
#		 LA
%		 US
#		 US
%
  Nucleoside Reverse Transcriptase Inhibitors 2,154 59 83,166 36
  non-Nucleoside Reverse Transcriptase Inhibitors 529 15 23,933 10
  Protease Inhibitors 919 25 33,813 15
  Opportunistic Infections/Other 22 1 87,746 38
  Total 3,624 100 228,771 100

 
Federal ADAP Funds Used for Insurance Purchasing/Maintenance, FY 2002  
  LA
$		 US
$
   300,000 18,486,544

 
ADAP Formularies, Number of Medications by Drug Class, 2002  
  LA
#		 US
#
  Nucleoside Reverse Transcriptase Inhibitors 9 NA
  Protease Inhibitors Covered 6 NA
  Non-nucleosides Covered 3 NA
  OI Prophylaxis Covered 0 NA
  Other Medications Covered 0 NA
  Total 18 NA

 
ADAP Emergency Cost Containment Measures, February 2003  
  LA
 		 US
 
  Has ADAP Emergency Cost Containment Measures in Place No 16 Yes
  Notes